Surgical Research Laboratory, Department of Surgery, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Br J Surg. 2013 Oct;100(11):1498-504. doi: 10.1002/bjs.9243.
Fibrin sealants are used in pancreatic surgery to prevent leakage of pancreatic fluid and reduce associated complications. The efficacy of this approach is unclear.
Fibrin clots were generated in vitro from two commercially available liquid fibrin sealants (Tissucol Duo® and Evicel®) and the carrier-bound fibrin sealant Tachosil®, and exposed to normal saline or human pancreatic fluid. Stability of the sealants was assessed by release of the fibrin and collagen degradation products, D-dimer and hydroxyproline. The effect of protease inhibitors on sealant breakdown was assessed.
Clots generated from liquid fibrin sealants degraded rapidly in pancreatic fluid, but not in normal saline. D-dimer release from fibrin clots by pancreatic fluid was approximately 1700 µg/ml after 24 h and less than 20 µg/ml by saline. Pancreatic fluid, but not normal saline, degraded both the fibrin and collagen component of Tachosil®. After 6 h, mean(s.e.m.) D-dimer levels in pancreatic fluid exposed to Tachosil® were 850(183) ng/ml, compared with 60(6) ng/ml in normal saline. The mean(s.e.m.) hydroxyproline concentration in pancreatic fluid was 497(17) µg/ml after a 24-h exposure to Tachosil®, compared with 26(12) µg/ml in normal saline. Protease inhibitors significantly inhibited breakdown of liquid sealants (D-dimer levels less than 50 µg/ml after 24 h) and Tachosil® (D-dimer release 179(12) ng/ml at 6 h; hydroxyproline release 181(29) µg/ml at 24 h).
Proteases in pancreatic juice effectively degrade both liquid and carrier-bound fibrin sealants in vitro. The use of these products in pancreatic surgery with the aim of preventing leakage of pancreatic fluid is not supported by this experimental study.
纤维蛋白胶在胰腺外科中用于防止胰液渗漏并减少相关并发症。这种方法的疗效尚不清楚。
从两种市售的液体纤维蛋白胶(Tissucol Duo®和 Evicel®)和载体结合的纤维蛋白胶 Tachosil®中体外生成纤维蛋白凝块,并将其暴露于生理盐水或人胰腺液中。通过释放纤维蛋白和胶原蛋白降解产物二聚体(D-dimer)和羟脯氨酸来评估密封剂的稳定性。评估蛋白酶抑制剂对密封剂分解的影响。
液体纤维蛋白胶生成的凝块在胰腺液中迅速降解,但在生理盐水中不会。胰腺液中纤维蛋白凝块释放的二聚体在 24 小时后约为 1700μg/ml,而生理盐水则小于 20μg/ml。胰腺液会降解 Tachosil®中的纤维蛋白和胶原蛋白成分,但生理盐水不会。6 小时后,暴露于 Tachosil®的胰腺液中的平均(标准误)二聚体水平为 850(183)ng/ml,而生理盐水为 60(6)ng/ml。暴露于 Tachosil®的胰腺液中羟脯氨酸的平均(标准误)浓度在 24 小时后为 497(17)μg/ml,而生理盐水为 26(12)μg/ml。蛋白酶抑制剂显著抑制了液体密封剂的分解(24 小时后二聚体水平小于 50μg/ml)和 Tachosil®的分解(6 小时时二聚体释放 179(12)ng/ml;24 小时时羟脯氨酸释放 181(29)μg/ml)。
胰液中的蛋白酶可有效降解体外的液体和载体结合的纤维蛋白胶。本实验研究不支持在胰腺手术中使用这些产品来预防胰液渗漏。